Candidate autoantibodies for primary Sjögren's syndrome: where are they now?

• Published in: Clinical and experimental rheumatology Vol. 40; no. 12; p. 2387
• Main Authors: He, Jianna, Jiang, Jocelyn, Baumgart, Karl
• Format: Journal Article
• Language: English
• Published: Italy 01-12-2022
• Subjects: Antibodies, Antinuclear; Autoantibodies; Biomarkers; Humans; Sjogren's Syndrome
• ISSN: 0392-856X
• DOI: 10.55563/clinexprheumatol/vmqtz4

Although ANA, SSA and SSB antibody testing are universally accepted biomarkers for Sjögren's syndrome (SS) diagnosis, they do not occur in all patients. Up to 18% of SS patients are seronegative, with potential for delayed or missed diagnosis. There are no clinically available autoantibodies with predictive value for SS end-organ complications. Over the last three decades, novel autoantibodies for SS diagnosis and monitoring have been identified but few have transitioned from research studies to clinical use. We performed a literature review of candidate serum autoantibodies to examine their persistence in the literature and potential clinical utility. Of the nineteen autoantibodies we identified, AQP5, SP-1, CA6, and PSP Abs have the most promise. Larger cohort studies are needed to determine their potential contribution in SS management.